{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T03:35:16Z","timestamp":1773632116955,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BioMarin Brasil Farmac\u00eautica LTDA"},{"name":"BioMarin Brasil Farmac\u00eautica LTDA."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ymgmr.2020.100572","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:26:44Z","timestamp":1582802804000},"page":"100572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America"],"prefix":"10.1016","volume":"23","author":[{"given":"Martha L.","family":"Solano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Fainboim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Politei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria L.","family":"Porras-Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina F. Moura","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe Mendez","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernan","family":"Amartino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Maria","family":"Satiz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafne D.G.","family":"Horovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula F.V.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel S.","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Louren\u00e7o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ymgmr.2020.100572_bb0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/BF02830840","article-title":"Maroteaux-Lamy syndrome","volume":"71","author":"Lakhotia","year":"2004","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0010","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jpeds.2004.01.052","article-title":"The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations","volume":"144","author":"Muenzer","year":"2004","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100572_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0020","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidosis","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgmr.2020.100572_bb0025","first-page":"59e66","article-title":"Mortality in patients with Morquio syndrome A","volume":"15","author":"Lavery","year":"2015","journal-title":"JIMD Rep."},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2020.100572_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","article-title":"Mucopolysaccharidosis IVA and glycosaminoglycans","volume":"120","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s10038-018-0534-8","article-title":"Recent trends in mucopolysaccharidosis research","volume":"64","author":"Kobayashi","year":"2018","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100572_bb0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/156652311794940791","article-title":"Therapies for neurological disease in the mucopolysaccharidoses","volume":"11","author":"Anson","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2002.tb03115.x","article-title":"Enzyme replacement therapy: from concept to clinical practice","volume":"439","author":"Sly","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12881-016-0284-4","article-title":"12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment","volume":"17","author":"Gabrielli","year":"2016","journal-title":"BMC Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0065","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15017850","article-title":"Short communication impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings","volume":"15","author":"Franco","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10545-006-0237-8","article-title":"Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I","volume":"29","author":"Anbu","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"16","key":"10.1016\/j.ymgmr.2020.100572_bb0075","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/ajmg.a.31831","article-title":"Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy","volume":"143A","author":"Wegrzyn","year":"2007","journal-title":"Am. J. Med. Genet. A"},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100572_bb0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2013.08.019","article-title":"Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases","volume":"111","author":"Jurecka","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0085","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ymgme.2012.08.013","article-title":"Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature","volume":"107","author":"Jurecka","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.ymgmr.2020.100572_bb0090","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","article-title":"Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome):10-year follow-up of patients who previously participated in an MPS VI Survey Study","volume":"164A","author":"Giugliani","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"issue":"6","key":"10.1016\/j.ymgmr.2020.100572_bb0095","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0100","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/ajmg.a.38459","article-title":"Genotypic-phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey","volume":"173","author":"K\u0131l\u0131\u00e7","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100572_bb0105","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100572_bb0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","article-title":"Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet. J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","article-title":"Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet. J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100572_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgmr.2015.09.002","article-title":"Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: six years follow-up of four children","volume":"5","author":"Horovitz","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100572_bb0135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"International consensus panel on management and treatment of mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-018-0560-3","article-title":"Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists","volume":"44","author":"Boffi","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2013.02.013","article-title":"Up to five years experience with 11 mucopolysaccharidosis type VI patients","volume":"109","author":"Brands","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100572_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.15171\/bi.2018.17","article-title":"Enzyme replacement therapies: what is the best option?","volume":"8","author":"Safary","year":"2018","journal-title":"Bioimpacts."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100572_bb0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaip.2015.11.012","article-title":"Diagnosis and management of infusion-related hypersensitivity reactions to enzyme replacement therapy for lysosomal diseases: the role of desensitization","volume":"4","author":"Aranda","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100572_bb0175","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/pai.12209","article-title":"Laronidase hypersensitivity and desensitization in type I mucopolysaccharidosis: a case report","volume":"25","author":"Ensina","year":"2014","journal-title":"Pediatr. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2005.11.007","article-title":"Mucopolysaccharidoses and the eye","volume":"51","author":"Ashworth","year":"2006","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archopht.1974.03900060189006","article-title":"Electrophysiological and psychophysical findings in hunter syndrome","volume":"91","author":"Abraham","year":"1974","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0190","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"New Eng. J. Med."},{"issue":"11","key":"10.1016\/j.ymgmr.2020.100572_bb0195","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","article-title":"Long-term outcomes of systemic therapies for hurler syndrome: an international multicenter comparison","volume":"20","author":"Eisengart","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0205","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0215","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000500804","article-title":"Recovery of vision following enzyme replacement therapy in a patient with mucopolysaccharidosis type II, hunter syndrome","volume":"10","author":"Yamanishi","year":"2019","journal-title":"Case Rep. Ophthalmol."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0220","series-title":"Inborn Metabolic Diseases: Diagnosis and Treatment","article-title":"Mucopolysaccharidoses, oligosaccharidoses and sialic acid disorders","volume":"577","author":"Jones","year":"2016"},{"issue":"6","key":"10.1016\/j.ymgmr.2020.100572_bb0225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0230","article-title":"The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: a longitudinal analysis","volume":"20","author":"Kenth","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100572_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0883-6","article-title":"Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA","volume":"13","author":"Lin","year":"2018","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0240","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymgme.2014.12.001","article-title":"Therapies for the bone in mucopolysaccharidoses","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymgmr.2016.10.001","article-title":"30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: about one case","volume":"9","author":"Do Cao","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0250","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2741\/4490","article-title":"Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment","volume":"22","author":"Harmatz","year":"2017","journal-title":"Front. Biosci. (Landmark Ed)."},{"issue":"6","key":"10.1016\/j.ymgmr.2020.100572_bb0255","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100572_bb0260","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10545-013-9649-4","article-title":"Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy","volume":"37","author":"Kampmann","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2020.100572_bb0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgmr.2016.04.003","article-title":"Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: a case series","volume":"7","author":"Lin","year":"2016","journal-title":"Mol. Genet. Metab. Rep."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920300185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920300185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T16:03:47Z","timestamp":1598457827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426920300185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":52,"alternative-id":["S2214426920300185"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100572","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100572"}}